newsfilter
← Latest News
Business Wire·

Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting

Two oral presentations on etavopivat include data from Forma's Phase 1 open label extension trial in sickle cell disease demonstrating a favorable tolerability profile consistent with previously-reported results Additional data supports improvement